Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tyrosine-kinase-2-inhibitor-shows-benefit-atopic-dermatitis-2026a100019m?src=rss
Author :
Publish date : 2026-01-14 16:05:00
Copyright for syndicated content belongs to the linked Source.